Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Khat refers to the leaves and fresh shoots of Catha edulis, a flowering evergreen shrub native to East Africa and the Arabian Peninsula. It contains psychoactive compounds, primarily cathinone and cathine, which are structurally similar to amphetamine. Cathinone is the principal active stimulant and is about 10 times more potent than cathine. These compounds produce stimulant and euphoric effects when the leaves are chewed. Khat has been used traditionally since the thirteenth century to elevate mood, combat fatigue, and suppress appetite. The stimulant effect begins to diminish within 48 hours after harvesting as cathinone degrades into cathine and norephedrine. The World Health Organization (WHO) has classified khat as a drug that can create psychological dependence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on khat.